论文部分内容阅读
目的观察雷贝拉唑联合莫沙比利治疗反流性食管炎的临床疗效。方法将102例反流性食管炎患者随机分为治疗组52例和观察组50例。治疗组:雷贝拉唑10mg1次/d,莫沙比利5mg,3次/d;对照组:法莫替丁20mg,2次/d莫沙比利5mg,3次/d。于治疗后8周观察烧心,反酸,胸痛等症状改善情况,并复查胃镜,观察镜下治愈率。结果治疗组临床有效率96。2%,内镜下有效率94.2%;对照组临床有效率72%,内镜下有效率70%,两组比较差异有统计学意义。结论雷贝拉唑联合莫沙比利治疗反流性食管炎比法莫替丁联合莫比利具有更好的疗效。
Objective To observe the clinical efficacy of rabeprazole and mosapride in the treatment of reflux esophagitis. Methods A total of 102 patients with reflux esophagitis were randomly divided into treatment group (52 cases) and observation group (50 cases). Treatment group: rabeprazole 10mg 1 times / d, mosapride 5mg, 3 times / d; control group: famotidine 20mg, 2 times / d mosapride 5mg, 3 times / d. Eight weeks after treatment, the symptoms such as heartburn, acid reflux and chest pain were observed. Gastroscopy was performed to observe the cure rate. Results The clinical effective rate was 96.2% in the treatment group and 94.2% in the endoscopic treatment group. The clinical effective rate was 72% in the control group and 70% in the endoscopic group. The difference between the two groups was statistically significant. Conclusion Rabeprazole combined with mosapride in the treatment of reflux esophagitis is better than famotidine combined with mopilib.